- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06810206
A Comparison Between The Efficacy of Modified Thoracoabdominal Plane Block Via Perichondral Approach (M-TAPA) And External Oblique Intercostal Plane Block (EOIPB) in Patients Undergoing Laparoscopic Cholecystectomy Surgeries (LC)
A Comparison Between The Efficacy of Modified Thoracoabdominal Plane Block Via Perichondral Approach (M-TAPA) And External Oblique Intercostal Plane Block (EOIPB) in Patients Undergoing Laparoscopic Cholecystectomy Surgeries (LC): A Double-Blinded Randomized Comparative Study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Miran M Abdelaziz Raslan, MSC
- Phone Number: 00201140646969
- Email: miranrs1994@gmail.com
Study Contact Backup
- Name: Nora A Agiza, MD
- Phone Number: 00201001881060
- Email: noraagiza@gmail.com
Study Locations
-
-
-
Cairo, Egypt
- Faculity of medicine , Kasr Al Aini Hospitals , Cairo University
-
Contact:
- Nora A Agiza, MD
- Phone Number: 00201001881060
- Email: noraagiza@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged 18-65 years
- Scheduled for Laparoscopic cholecystectomy surgery
- ASA (American Society of Anaesthesiologists) physical status I-II
Exclusion Criteria:
- Known allergy to local anaesthetics
- Coagulopathy or anticoagulant use
- Infection at the site of block
- Chronic pain conditions
- Advanced liver or kidney failure
- History of abdominal surgery or trauma
- Alcohol or drug use
- Refusal to participate
- Chronic opioid consumption
- Use of painkillers in the preoperative 24hours
- Conversion to open surgery
- Body mass index ( BMI ) > 35
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group A
Group A: 30 patients will receive the MTAPA.
|
transversus abdominis, internal oblique, and external oblique muscles will be identified on the costochondral angle in the sagittal plane at the 10th costal margin.
deep angle will be given to the costochondral angle at the edge of the 10th costa with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline.
The needle will be inserted in the cranial direction using the in-plane technique, and the needle tip will be moved to the posterior aspect of the 10th costal cartilage, and saline (5 ml) will be injected to confirm the location by observing dissection between internal oblique muscle and transversus abdominis muscle under the 10th costal cartilage, and local anesthetic will be injected into the lower surface of the chondrium.
The local anesthetic to be used is bupivacaine 0.25% with Ultrasound Siemens® ACUSON X300 portable scanner with a high frequency linear transducer (10 MHz) using A Quincke 22 G .
x 3½ in.
(0.7x88 mm) A spinal needle
Other Names:
|
|
Active Comparator: Group B
Group B: 30 patients will receive the EOIPB.
|
The patients will be positioned in the supine position with the ipsilateral arm in abduction. The transducer will be positioned in a cephalad to caudad parasagittal plane at the anterior axillary line at the level of the sixth and seventh ribs in line with the xiphoid process. Using the in-plane technique, the needle will be advanced from cephalad to caudad until the tip lies in the plane between the external oblique muscle and intercostal muscles between the sixth and seventh ribs. Following hydro-dissection with 2 ml of 0.9% saline to confirm the correct needle tip position, LA injection will be given. The same procedure will then be repeated on the contralateral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
comparing the effectiveness of the modified thoracoabdominal plane block via perichondral approach versus the external oblique intercoastal plane block in reducing pain in laparoscopic cholecystectomy surgery's patients through calculating the mean NRS
Time Frame: . NRS scores will be recorded postoperatively upon arrival to PACU and it will be noted as point (0) and then at 20 minutes , and then after the 1st hour , and the at the 6th hour , 12 th hour and 24th hour for a total of 24-hour period.
|
Numerical Rating Score (NRS) for Pain severity will be measured with a NRS of 0, being no pain , while of 10 being worst pain imaginable.
NRS scores will be recorded postoperatively upon arrival to PACU and it will be noted as point (0) and then at 20 minutes , and then after the 1st hour , and the at the 6th hour , 12 th hour and 24th hour for a total of 24-hour period.
(11) Patients will be educated and familiarized with NRS scores in the preoperative period.
Postoperative, pain control regimen will be used for the two groups as Paracetamol 15mg/kg IV /6hours, Ketorolac 30mg IV /8hours.
If the patient's NRS pain score happens to be ≥ 4 points, 10 mg of intravenous nalbuphine Will be given , and the NRS will be repeated again after 15 minutes , if still > 4 , additional 10 mg IV nalbuphine will be given , with maximum dose of 20 mg per dose , can be repeated up to four times per day with maximum dose of 80 mg per day (18)
|
. NRS scores will be recorded postoperatively upon arrival to PACU and it will be noted as point (0) and then at 20 minutes , and then after the 1st hour , and the at the 6th hour , 12 th hour and 24th hour for a total of 24-hour period.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total opioid consumption in the first 24 hours postoperatively in mgs
Time Frame: postoperatively with a total of 24 hour
|
|
postoperatively with a total of 24 hour
|
|
Time to first mobilization in hours
Time Frame: postoperatively up to 24 hour
|
●The time to mobilization of the patients following surgery will be recorded in hours Mobilization will be defined as being able to at least sit on the edge of the bed.
|
postoperatively up to 24 hour
|
|
Incidence of block-related complications
Time Frame: postoperatively with a total of 24 hour
|
Incidence of block-related complications (e.g., hematoma, infection, nerve damage , LAST )
|
postoperatively with a total of 24 hour
|
|
Incidence of PONV.
Time Frame: every six hours for a total of 24 hour postoperatively
|
●Verbal descriptive scale for Postoperative Nausea and Vomiting (PONV) will be used with 0 = none , 1 = mild nausea , 2= moderate nausea , 3= vomiting once , 4= multiple vomiting .
|
every six hours for a total of 24 hour postoperatively
|
|
the Time to first rescue opioid
Time Frame: it will be measured postoperatively for a total period of 24 hour
|
the time to first rescue opioid will be noted and defined as the duration in hours that the patient lasted without the need of nalbuphine IV dose of 10 mg (NRS<4).
|
it will be measured postoperatively for a total period of 24 hour
|
|
evaluating the quality of recovery via the QOR-40 questionnaire.
Time Frame: the Quality of Recovery-40 (QoR-40) questionnaire will be used in PACU after 10 minutes from patient arrival to the PACU .
|
To evaluate the quality of recovery, the Quality of Recovery-40 (QoR-40) questionnaire will be used in PACU after 10 minutes from patient arrival to the PACU.
Scores range from a minimum of 40 (poor recovery) to a maximum of 200 (excellent recovery).
|
the Quality of Recovery-40 (QoR-40) questionnaire will be used in PACU after 10 minutes from patient arrival to the PACU .
|
|
identifying dermatomal coverage of each block via pinprick test.
Time Frame: Dermatomal coverage will be tested using pinprick test in PACU after evaluating the QoR-40 within the first hour postoperatively
|
Dermatomal coverage will be tested using pinprick test to evaluate the T3-L1 sensory levels in PACU after evaluating the QoR-40 ( since block will be administered after induction of anaesthesia ) .
Anterior and lateral cutaneous branches will be evaluated on a vertical line 3-5 cm from the midline and midaxillary lines, respectively.
A 3-point numerical scale (0 = no pain, 1 = decreasing pain, 2 = normal pain) will be used.
The values of 0 or 1 will be defined as effective .
The normal sense in the shoulder will be used for comparison.
(11,17)
|
Dermatomal coverage will be tested using pinprick test in PACU after evaluating the QoR-40 within the first hour postoperatively
|
|
evaluating the efficacy of each block in providing analgesia intraoperatively by measuring amount of fentanyl consumed in micrograms
Time Frame: intraoperatively
|
|
intraoperatively
|
|
time taken to adminsiter the block bilaterally
Time Frame: just after induction of anestheisa intraoperative
|
The time required to perform each bilateral block was recorded in minutes, beginning immediately after completion of skin sterilization and from the start of puncture to the end of LA infusion and ending upon completion of the bilateral local anesthetic injections.201
Block performance time was compared between the M-TAPA and EOIPB groups as an indicator of procedural feasibility and technical ease.
In addition, the relationship between block performance time and patient BMI was evaluated to determine whether either technique is less affected by increasing BMI, thereby providing evidence regarding its ease of implementation in patients with higher body mass.
|
just after induction of anestheisa intraoperative
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MD-462-2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.